Soluble urokinase plasminogen activator receptor (suPAR) is a novel, independent predictive marker of myocardial infarction in HIV-1-infected patients: a nested case-control study

LJH Rasmussen,1,* A Knudsen,2,3,* TL Katzenstein,4 J Gerstoft,4 N Obel,4 NR Jørgensen,5 G Kronborg,2 T Benfield,2 A Kjær,3 J Eugen-Olsen1 and A-M Lebech2

1Clinical Research Centre, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark, 2Department of Infectious Diseases, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark, 3Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark, 4Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark and 5Department of Diagnostics and Medicine, Research Centre for Aging and Osteoporosis, Copenhagen University Hospital Glostrup, Glostrup, Denmark

Objectives
Patients infected with HIV are at increased risk of myocardial infarction (MI). Increased plasma levels of the inflammatory biomarker soluble urokinase plasminogen activator receptor (suPAR) have been associated with increased risk of cardiovascular diseases (CVD), including MI in the general population. We tested suPAR as a predictive biomarker of MI in HIV-1-infected individuals.

Methods
suPAR levels were investigated in a nested case-control study of 55 HIV-1-infected cases with verified first-time MI and 182 HIV-1-infected controls with no known CVD. Controls were matched for age, gender, duration of antiretroviral therapy (ART), smoking and no known CVD. suPAR was measured in the four plasma samples available for each patient at different time-points: 1, Before initiation of ART; 2, 3 months after initiation of ART; 3, 1 year before the case’s MI; and 4, The last sample available before the case’s MI.

Results
In unadjusted conditional regression analysis, higher levels of suPAR were associated with a significant increase in risk of MI at all time-points. Patients in the third and fourth suPAR quartiles had a three- to 10-fold higher risk of MI compared to patients in the lowest suPAR quartile at all time-points. suPAR remained a strong significant predictor of MI, when adjusting for HIV-1 RNA, total cholesterol, triglycerides and high-density lipoprotein.

Conclusion
Elevated suPAR levels were associated with increased risk of MI in HIV-infected patients, suggesting that suPAR could be a useful biomarker for prediction of first-time MI in this patient group, even years before the event.

Keywords: atherosclerosis, biomarker, cardiovascular disease, inflammation, lipids

Accepted 28 July 2015

Introduction
In countries with free access to antiretroviral therapy (ART), infection with HIV has become a chronic manageable condition, and nonAIDS comorbidities have become an increasing concern. In particular, patients infected with HIV-1 are at increased risk of cardiovascular disease (CVD) [1–3], such as myocardial infarction (MI), with an estimated 50% increased risk beyond that
explained by recognized cardiovascular risk factors [4]. HIV-accelerated chronic inflammation and immune perturbation, despite ART, might be directly associated with vascular dysfunction and the accelerated development of CVD [1,5]. However, also ART itself has been suggested as a potential factor leading to increased risk of MI through disturbances in the lipid metabolism and/or a direct effect on the cardiovascular system [6]. Biomarkers related to inflammation and associated with risk of CVD may help identify those HIV-1-infected patients with the highest risk of disease and allow early and preventive intervention. Among the more promising biomarkers are interleukin 6 (IL-6), D-dimer, C-reactive protein (CRP) [7,8], soluble tumor necrosis factor receptor (sTNFR) I and –II [9], and, as we have recently shown in a sub group of the present cohort, plasminogen activator inhibitor-1 (PAI-1) [10].

Soluble urokinase plasminogen activator receptor (suPAR) is a stable plasma biomarker associated with inflammation and immune activation. suPAR can bind urokinase plasminogen activator (uPA) and has been suggested to act as a uPA-scavenger [11,12] thereby inhibiting the catalytic process mediated by uPA with possible implications of fibrinolysis inhibition.

suPAR is a strong prognostic marker of disease severity and mortality in different patient populations [13,14], including HIV-1-infected patients [15,16]. In the general population, increased plasma suPAR levels have been associated with an increased risk of CVD, including MI [14,17,18], but it remains unknown whether suPAR is a useful marker for CVD in HIV-1-infected patients.

In this study, we aimed to investigate the potential role of suPAR as a prognostic marker of first-time MI in patients with HIV.

Materials and methods

Design and study population

In a nested case-control study previously described [19], 55 HIV-1-infected patients with verified first-time MI were compared with 182 HIV-1-infected controls with no CVD event. Briefly, data were extracted from the Danish National Patient Register on patients given a diagnosis of ischaemic heart disease and HIV (International Classification of Diseases-10th Revision (ICD10) I20-25 and B20-24) from January 1998 to December 2008. Among these, patients registered in the Danish HIV Cohort Study (DHCS) were identified, and only patients with verified first-time MI according to international criteria were included in the study. Stored plasma samples from routine visits were analysed. Written informed consent for the storage and scientific analysis of blood samples was obtained from all participants and the study approved by the Scientific Ethical Committee of the Capital Region of Denmark (KF H-C-2008-108).

The date of the case’s MI served as index date for the selection of controls from the DHCS. Up to four controls were obtained per case. Individuals with diabetes and/or CVD, other than hypertension, were excluded. All patients in the study received ART. Controls were matched with their respective case for age at the time of MI ± 3 years, gender, duration of ART and smoking.

The study set-up included four plasma samples for each patient at four time-points: 1, Last available sample before initiation of ART; 2, 3 months after initiation of ART; 3, 1 year before the case’s MI; and 4, The last sample available before the case’s MI.

Plasma analysis of suPAR and blood lipids

Plasma samples were stored at −80 °C until the analysis of suPAR levels, using the commercially available CE/IVD approved suPARnostic® ELISA (ViroGates A/S, Birkerød, Denmark) according to the manufacturer’s instruction. The suPARnostic® ELISA has been validated to measure suPAR concentrations of 0.6–22 ng/mL. Total cholesterol, high-density lipoprotein (HDL) and triglycerides (TG) were analysed on a Vitros 5.1 Chemistry System (Ortho Clinical Diagnostics, New York, NY, USA). Very low-density lipoprotein (VLDL) was calculated by the formula TG (mmol/L) × 0.45, and LDL was calculated by the formula: total cholesterol (mmol/L) – [HDL (mmol/L) + VLDL (mmol/L)].

Statistical analysis

Conditional logistic regression was used to estimate odds ratios (OR) for the association of suPAR and MI and for the comparison of intergroup differences. Adjustment for co-variables was performed with multiple conditional regression analysis, and associations between all predictors and outcome were analysed for the full model. LDL and VLDL were not included in multiple conditional logistic regressions because they were calculated from the other lipids. Correlation analyses were performed on log-transformed values.

Tests for interaction were performed using a general linear model. The SPSS 20 software (IBM, Armonk, NY, USA) was used for all statistical analysis. A value of $P < 0.05$ was considered statistically significant.
Results

Patient characteristics

The study population included 55 cases and 182 matched controls. Study participant characteristics are shown in Table 1. More than 80% of all patients had suppressed viral load (HIV-1 RNA <400 copies/mL) and CD4 cell count above 400 cells/μL in plasma sample 4 and did not differ in ART regimen at any time-point. The cases, however, had a tendency towards higher values of total-cholesterol, LDL and TG, and lower HDL in all samples (Table 2).

suPAR levels are significantly associated with MI at all time-points

Figure 1 shows the median plasma suPAR levels at the four time-points. Cases had significantly higher suPAR levels compared to controls at all time-points [time-point 1: 5.2 ng/mL (3.6–7.7) vs. 4.2 ng/mL (3.0–6.1); time-point 2: 4.5 ng/mL (3.4–5.3) vs. 3.6 ng/mL (2.9–4.7); time-point 3: 4.3 ng/mL (3.5–5.2) vs. 3.4 ng/mL (2.7–4.3); time-point 4: 4.4 ng/mL (3.6–5.6) vs. 3.5 ng/mL (2.8–4.6); ranges in parentheses indicate IQR, P < 0.05].

In an unadjusted conditional regression analysis, an increase in suPAR of 1 ng/mL was associated with an increased risk of MI by 12% (95% CI: 1–25) at time-point 1, 26% (95% CI: 3–55) at time-point 2, 29% (95% CI: 6–56) at time-point 3, and 23% (95% CI: 5–45) at time-point 4 (P < 0.05 for all time-points; Table 3). In a multiple conditional regression analysis, suPAR was adjusted for total cholesterol, HDL, TG, and HIV-1 RNA. The univariate and multiple analyses between all predictors and outcome are shown in Table 3.

suPAR quartiles and risk of MI

Compared with patients in the lowest (1st) suPAR quartile, the risk of MI was significantly higher in the 3rd and 4th suPAR quartiles at all time-points (Fig. 2a). Especially 1 year before MI (time-point 3), there was a pronounced increase in risk of MI for patients in the 3rd and 4th suPAR quartiles with odds ratios of 7.41 (95% CI: 2.11–26.05, P < 0.01) and 10.38 (95% CI: 2.82–38.27, P < 0.001), respectively (Fig. 2a). But even before initiation of ART (time-point 1), there was an increased risk with odds ratios of 3.17 (95% CI: 1.05–9.59, P < 0.05) and 4.33 (95% CI: 1.44–13.03, P < 0.01) for the 3rd and 4th suPAR quartiles, respectively (Fig. 2a).

Table 1 Demographic characteristics of the HIV-1-infected patients with first-time myocardial infarction and the HIV-1-infected controls

| Variable                        | Cases | Controls | P    |
|---------------------------------|-------|----------|------|
| Number of patients              | 55    | 182      |      |
| Gender (male/female) (%)        | 50/5  | 167/15   | 0.84 |
| Age at time of MI/index date median (IQR), years | 49 (42–57) | 50 (43–57) | 0.77 |
| Smoking (never/previous/current) (%) | 3/8/44 | 6/14/80 | 0.12 |
| Duration of HIV before MI/index date median (IQR), years | 10 (6–17) | 10 (7–16) | 0.71 |
| Blood pressure systolic median (IQR) | 135 (120–149) | n = 36 | 0.09 |
| Lipid-lowering treatment (%)*   | 6     | 4        | 0.6  |

*Within the study period.

suPAR levels predict MI independently of HIV-1 RNA and blood lipids

In a multiple conditional logistic regression analysis of suPAR quartiles adjusting for HIV-1 RNA, total cholesterol, HDL, and triglycerides, suPAR remained an independent predictor of MI. At time-point 3, risk of MI remained strongly associated with high suPAR with odds ratios of 7.18 (95% CI: 1.97–26.24, P < 0.01) and 9.09 (95% CI: 2.37–34.87, P < 0.01) for patients in the 3rd and 4th suPAR quartiles, respectively, compared to patients in the lowest suPAR quartile (Fig. 2b). Furthermore, the 4th suPAR quartile at time-point 1 (before ART) and time-point 2 (3 months after ART) were also associated with an increased risk of MI [OR (95% CI): 7.94 (1.35–46.79), P < 0.05, and OR (95% CI): 4.76 (1.41–16.10), P = 0.01] (Fig. 2b).

In the multiple analyses, total cholesterol was significantly associated with MI at time-point 1 [OR (95% CI): 1.72 (1.07–2.76), P < 0.05], time-point 2 [OR (95% CI): 1.65 (1.15–2.38), P < 0.01], and time-point 4 [OR (95%
Table 2 Characteristics of the study groups at the four sample time-points: 1, the last sample available before initiation of ART; 2, 3 months after initiation of ART; 3, 1 year before the case's MI/index date; and 4, the last sample available before the case's MI/index date.

|                      | Sample 1 |                  | Sample 2 |                  | Sample 3 |                  | Sample 4 |                  |
|----------------------|----------|------------------|----------|------------------|----------|------------------|----------|------------------|
|                      | Cases    | Controls         | \(P\)    | Cases            | Controls | \(P\)            | Cases    | Controls         | \(P\)    |
| CD4 count, cells/μL | 170 (81–235) | 199 (84–296) | 0.13     | 256 (186–383)   | 271 (150–377) | 0.73   | 433 (279–660)   | 500 (310–730) | 0.32 |
| HIV-1 RNA copies/mL | 114 (33–150) | 271 (84–296) | 0.27     | 51 (28–399)     | 199 (20–399) | 0.66   | 39 (19–1590)    | 38 (19–43) | 0.12 |
| Total cholesterol mmol/L | 4.8 (3.9–5.1) | 4.2 (3.5–4.3) | 0.04     | 5.4 (4.4–6.5)   | 4.8 (4.1–5.8) | 0.03   | 5.1 (4.2–6.6)   | 5.1 (4.4–6.0) | 0.41 |
| LDL mmol/L          | 3.0 (2.1–3.6) | 2.5 (1.9–3.2) | 0.04     | 3.1 (2.3–4.6)   | 2.9 (2.1–3.6) | 0.06   | 3.1 (2.1–4.6)   | 3.0 (2.3–3.8) | 0.40 |
| Triglycerides mmol/L | 1.9 (1.4–2.9) | 1.7 (1.2–2.3) | 0.06     | 2.3 (1.8–3.2)   | 2.1 (1.3–2.9) | 0.05   | 2.6 (1.9–3.1)   | 2.1 (1.4–2.9) | 0.14 |
| HDL mmol/L          | 0.72 (0.7–0.9) | 0.78 (0.6–0.3) | 0.12     | 0.9 (0.7–1.0)   | 1.0 (0.8–1.2) | 0.15   | 0.9 (0.7–1.1)   | 1.1 (0.9–1.3) | 0.03 |
| NRTI (%)            | NA       | NA               | NA       | 100              | 98       | 0.49            | 98       | 98               | 0.91 |
| PI (%)              | NA       | NA               | NA       | 81               | 77       | 0.23            | 62       | 58               | 0.62 |
| NNRTI (%)           | NA       | NA               | NA       | 15               | 21       | 0.12            | 46       | 41               | 0.37 |
| Other ART           | NA       | NA               | NA       | 0                | 0        | NA              | 0        | 0                | NA   |

\(P\)-values are calculated with conditional logistic regression. ART, antiretroviral therapy; HDL, high-density lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein; NNRTI, non-nucleoside reverse-transcriptase inhibitors; NRTI, nucleoside reverse-transcriptase inhibitors; PI, protease inhibitors.
We have previously published data on PAI-1 and the risk of MI at time-points 3 and 4 in a sub-group of this sample [10] and we therefore performed a correlation analysis of suPAR and PAI-1 at time-points 3 and 4, but no correlation was found (data not shown). No interaction was found between case-control status and the correlated parameters.

**Discussion**

In this case-control study, we show for the first time that suPAR is a strong independent predictor of MI among HIV-1-infected patients. Elevated suPAR levels were strongly and significantly associated with subsequent development of first-time MI, even years before the event. The association persisted after adjustment for HIV-1 viral load and blood lipids.

Inflammatory biomarkers such as CRP, D-dimer and IL-6 have all been suggested to predict cardiovascular events in HIV-1-infected patients, even with full viral suppression obtained by ART [7–9]. However, it remains debated whether the ART itself is involved in the development of MI among HIV-1-infected patients [1,6]. Our findings seem to suggest that ART did not play a direct role in the development of MI, given that suPAR levels among cases were already increased before initiation of ART. This indicates that the cases had an inherent risk of CVD unrelated to their HIV treatment or, in other words, that suPAR predicts MI through pathways independent of ART use.

suPAR has previously been shown to predict mortality in treatment-naïve HIV-1-infected patients [16]. In HIV-patients initiating ART, mortality was concentrated in the highest suPAR quartile, while patients with a low suPAR level had a low risk of mortality despite low CD4 cell count and low body weight [15]. Thus, suPAR appears to add significant information to other measures of poor prognosis in HIV-infected patients.

---

**Table 3**

|                   | Sample 1       | Sample 2       | Sample 3       | Sample 4       | Sample 4       |
|-------------------|----------------|----------------|----------------|----------------|----------------|
|                   | Univariate     | Multiple       | Univariate     | Multiple       | Univariate     | Multiple       | Univariate     | Multiple       |
| suPAR             | 1.12 (1.01–1.25) | 1.13 (0.95–1.34) | 1.26 (1.03–1.55) | 1.27 (1.01–1.61) | 1.29 (1.06–1.56) | 1.24 (1.01–1.52) | 1.23 (1.05–1.45) | 1.33 (1.09–1.63) |
| Total cholesterol  | 1.41 (1.02–1.94) | 1.72 (1.07–2.76) | 1.36 (1.04–1.78) | 1.65 (1.15–2.38) | 1.11 (0.87–1.41) | 1.28 (0.95–1.71) | 1.24 (1.00–1.53) | 1.45 (1.12–1.89) |
| HDL               | 0.37 (0.11–1.27) | 0.30 (0.02–5.16) | 0.45 (0.15–1.35) | 0.36 (0.07–1.89) | 0.31 (0.11–0.90) | 0.34 (0.09–1.27) | 0.44 (0.18–1.09) | 0.42 (0.12–1.49) |
| Triglycerides     | 1.46 (0.95–2.16) | 1.49 (0.78–2.88) | 1.38 (0.89–1.92) | 1.35 (0.89–2.06) | 1.21 (0.94–1.56) | 1.01 (0.76–1.35) | 1.25 (0.97–1.62) | 1.08 (0.78–1.49) |
| logHIV-1 RNA       | 1.53 (1.02–2.28) | 1.62 (1.04–2.52) | 0.99 (0.68–1.48) | 0.98 (0.63–1.47) | 1.39 (1.06–1.82) | 1.33 (1.00–1.76) | 1.36 (0.96–1.91) | 1.32 (0.91–1.91) |

Numbers shown are odds ratios (95% confidence intervals).

HDL, high-density lipoprotein; suPAR, soluble urokinase plasminogen activator receptor.
We found that suPAR levels were lower in both cases and controls at the sampling points after initiation of ART therapy, which correlates well with previous findings [20,21]. suPAR has been suggested to be a marker of metabolic disturbances, such as lipoatrophy, dyslipidemia and insulin resistance, in HIV-infected patients [22,23], which are all potential cofactors in the pathogenesis of MI among HIV-infected patients, but in this study suPAR predicted MI independently of lipid values. Together, these findings suggest that beside the risk associated with the traditional risk factors, such as total cholesterol and LDL, suPAR may reflect a different pathogenesis of a more inflammatory nature.

Fig. 2 The risk of myocardial infarction (odds ratios, 95% CI) for patients with plasma suPAR levels in the upper three quartiles compared to the lowest quartile at four different time-points: 1, the last sample available before initiation of ART; 2, 3 months after initiation of ART; 3, 1 year before the case’s MI/index date; and 4, the last sample available before the case’s MI/index date. (a) Unadjusted and (b) adjusted for HIV-1 viral load, total cholesterol, HDL and triglycerides. ART, antiretroviral therapy; CI, confidence interval; HDL, high-density lipoprotein; MI, myocardial infarction; suPAR, soluble urokinase plasminogen activator receptor.

PAI-1 has previously been associated with MI in a subgroup of this cohort [10], and as suPAR can act as a uPA-scavenger our findings in this study cohort could point to a theory of hypercoagulability in the development of MI in HIV-1-infected patients, even with full viral suppression. However, we found no correlation between PAI-1 and suPAR in a sub-population of this cohort. The contribution of a hypercoagulable state to morbidity and mortality in HIV has been observed in other studies, showing that D-dimer is associated with CVD and mortality in HIV-1-infected patients [7,9,24].

The present results introduce suPAR as a potential novel inflammatory marker of cardiovascular events in HIV-infected patients with a >10-fold increase in risk of MI for patients with the highest suPAR levels. The use of suPAR as an indicator/surrogate marker for the chronic inflammation associated with increased cardiovascular risk and other nonAIDS-related morbidities may markedly improve the risk stratification of routinely followed HIV-patients and may aid in the identification of those patients mostly at risk of CVD events beyond the information provided by traditional risk factors; a property of suPAR, which is also observed in the general population [17,18]. Intriguingly, suPAR predicted the cardiovascular events even before the initiation of ART and may therefore be of guidance in both the choice of ART and direct focus towards early signs of co-morbidities in this population at risk.

The study has some limitations. The case-control design is associated with the risk of selection bias and residual confounding, and furthermore, the number of cases in the study was low. We have no information on tobacco use or smoking intensity on an individual basis. Therefore, we cannot exclude the possibility that cases had higher intensity of smoking, which has been found to correlate with suPAR levels [25]. Furthermore, it is important to underline that there is a higher percentage of previous smokers among the controls, causing a slight skewness of the data. Another limitation to this study is the lack of measurements of other competent inflammatory markers, such as IL-6 and TNF receptors, which has recently been shown to be associated with nonAIDS-defining events [9]. However, suPAR has previously been shown to be positively correlated with sTNFR-II and IL-6 in HIV-1-infected individuals [21,22], suggesting that these inflammatory markers reflect similar aspects of HIV-associated inflammation. As PAI-1 was only analyzed in a subgroup of the cohort, it is not possible to adjust for PAI-1 in the full model. All of the necessary parameters for the creation of an individual cardiovascular risk score, such as the Framingham risk score, were

© 2015 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association. HIV Medicine (2016), 17, 350–357
not registered, and we are therefore unable to test if the addition of suPAR to an existing risk score could increase the AUC.

Conclusion

In conclusion, this nested case-control study of 55 cases and 182 controls showed that elevated plasma suPAR levels were independently associated with an increased risk of developing first-time MI in an HIV-1-infected population. Thus, suPAR may be a new risk marker in the monitoring and management of comorbidities among HIV-1-infected patients even years before the event.

Acknowledgements

We gratefully acknowledge funding from the Danish Heart Foundation, the Danish Medical Research Council, and the Research Foundation of the Capital Region of Denmark. The funders had no role in study design, data collection and analysis, or preparation of manuscript.

Conflicts of interest: JEO is a founder, shareholder, and board member of ViroGates A/S, Denmark, the company that produces the suPARnostic® assay. JEO is also an inventor on a patent on suPAR and risk. Copenhagen University Hospital Hvidovre, Denmark, owns the patent, which is licensed to ViroGates A/S.

References

1 Hemkens LG, Bucher HC. HIV infection and cardiovascular disease. Eur Heart J 2014; 35: 1373–1381.
2 Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92 : 2506–2512.
3 Obel N, Thomsen HF, Kronborg G et al. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis 2007; 44 : 1625–1631.
4 Freiberg M, Chang C, Kuller LH et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013; 173 : 614–622.
5 Hsue PY, Deeks SG, Hunt PW. Immunologic basis of cardiovascular disease in HIV-infected adults. J Infect Dis 2012; 205 [Suppl 3]: S375–S382.
6 Worm SW, Sahin C, Weber R et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201 : 318–330.
7 Duprez DA, Neuhaus J, Kuller LH et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One 2012; 7 : e44454.
8 Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr 2009; 51 : 268–273.
9 Tenorio AR, Zheng Y, Bosch RJ et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis 2014; 210 : 1248–1259.
10 Knudsen A, Katzenstein TL, Benfield T et al. Plasma plasminogen activator inhibitor-1 predicts myocardial infarction in HIV-1-infected individuals. AIDS 2014; 28 : 1171–1179.
11 Masucci MT, Pedersen N, Blasi F. A soluble, ligand binding mutant of the human urokinase plasminogen activator receptor. J Biol Chem 1991; 266 : 8655–8658.
12 Piccoletta M, Festuccia C, Millimaggi D et al. suPAR, a soluble form of urokinase plasminogen activator receptor, inhibits human prostate cancer cell growth and invasion. Int J Oncol 2008; 32 : 185–191.
13 Thuno M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers 2009; 27 : 157–172.
14 Eugen-Olsen J, Andersen O, Linneberg A et al. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med 2010; 268 : 296–308.
15 Oliveira I, Andersen A, Furtado A et al. Assessment of simple risk markers for early mortality among HIV-infected patients in Guinea-Bissau: a cohort study. BMJ Open 2012; 2 : e001587.
16 Sidenius N, Sier C, Ullum H et al. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 2000; 96 : 4091–4095.
17 Persson M, Ostling G, Smith G et al. Soluble urokinase plasminogen activator receptor: a risk factor for carotid plaque, stroke, and coronary artery disease. Stroke 2014; 45 : 18–23.
18 Lyngbæk S, Marott JL, Sehested T et al. Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score. Int J Cardiol 2013; 167 : 2904–2911.
19 Knudsen A, Møller HJ, Katzenstein TL et al. Soluble CD163 does not predict first-time myocardial infarction in patients...
infected with human immunodeficiency virus: a nested case-control study. *BMC Infect Dis* 2013; 13: 230.

20 Langkilde A, Petersen J, Klausen HH, Henriksen JH, Eugen-Olsen J, Andersen O. Inflammation in HIV-infected patients: impact of HIV, lifestyle, body composition, and demography – a cross sectional cohort study. *PLoS One* 2012; 7: e51698.

21 Ostrowski S, Katzenstein T, Pedersen M *et al.* Plasma levels of intact and cleaved urokinase receptor decrease in HIV-1-infected patients initiating highly active antiretroviral therapy. *Scand J Immunol* 2006; 63: 478–486.

22 Andersen O, Eugen-Olsen J, Kofoed K, Iversen J, Haugaard SB. Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy. *J Med Virol* 2008; 80: 209–216.

23 Fourie CMT, Van Rooyen JM, Kruger A *et al.* Soluble urokinase plasminogen activator receptor (suPAR) is associated with metabolic changes in HIV-1-infected Africans: a prospective study. *Inflammation* 2012; 35: 221–229.

24 Ford ES, Greenwald JH, Richterman AG *et al.* Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection. *AIDS* 2010; 24: 1509–1517.

25 Haupt TH, Kallemose T, Ladelund S *et al.* Risk factors associated with serum levels of the inflammatory biomarker soluble urokinase plasminogen activator receptor in a general population. *Biomark Insights* 2014; 9: 91–100.